Format

Send to

Choose Destination
See comment in PubMed Commons below
J Atten Disord. 2009 Jan;12(4):316-29. doi: 10.1177/1087054708322986. Epub 2008 Sep 24.

Simulated driving changes in young adults with ADHD receiving mixed amphetamine salts extended release and atomoxetine.

Author information

1
Cognitive Research Corporation, St. Petersburg, FL 33701, USA. gkay@cogres.com

Abstract

BACKGROUND:

Psychostimulant treatment may improve simulated driving performance in young adults with attention-deficit/hyperactivity disorder (ADHD).

METHOD:

This was a randomized, double-blind, placebo-controlled, crossover study of simulated driving performance with mixed amphetamine salts-extended release (MAS XR) 50 mg/day (Cohort 1) and atomoxetine 80 mg/day (Cohort 2) in young adults with ADHD.

RESULTS:

Adults aged 19 to 25 years with AD/HD (N = 19) who were administered MAS XR significantly improved overall simulated driving performance versus placebo up to 12 hours after dosing. In contrast, there were no statistically significant differences in simulated-driving-performance scores between atomoxetine and placebo. At endpoint, MAS XR reduced ADHD Rating Scale scores > or = 30% in 80% of subjects, whereas atomoxetine achieved this level of improvement for 40%.

LIMITATIONS:

Small sample size and use of simulated driving may limit generalizability of the findings.

CONCLUSION:

MAS XR in young adults with ADHD yields significant improvements in simulated driving performance and ADHD symptoms.

PMID:
18815438
DOI:
10.1177/1087054708322986
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center